Acrivon Therapeutics, Inc. 8K

Acrivon Therapeutics reported Q2 2026 financial results, pipeline progress for ACR-368, ACR-2316 and a CDK11 inhibitor, and liquidity expected to fund operations into late 2027.

On August 12, 2026, Acrivon Therapeutics, Inc. reported its financial results for the quarter ended June 30, 2026, highlighting continued clinical advancement of its lead oncology programs ACR-368 and ACR-2316, progress of an AP3-driven CDK11 inhibitor into IND-enabling studies, and a cash, cash equivalents and marketable securities position of $90.0 million expected to fund operations into the fourth quarter of 2027, while disclosing a reduced quarterly net loss of $18.0 million compared to the prior year period.

Filing Facts

CIK

1781174

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-346859

Alert Tier

5